Phase I dose escalation study of IO-108, an anti-LILRB2 antibody, in patients with advanced solid tumors.
Taylor MH, Naing A, Powderly J, Woodard P, Chung L, Lin WH, Tian H, Siemers N, Xiang H, Deng R, Hong K, Valencia D, Huang T, Zhu Y, Liao XC, Schebye XM, Patel MR.
Taylor MH, et al. Among authors: liao xc.
J Immunother Cancer. 2024 Nov 20;12(11):e010006. doi: 10.1136/jitc-2024-010006.
J Immunother Cancer. 2024.
PMID: 39567210
Free PMC article.
Clinical Trial.